StockPriceToday

AngioDynamics Inc. (ANGO)

ANGO stock price

AngioDynamics Inc. develops and manufactures medical devices for minimally invasive procedures in oncology and vascular applications.

About AngioDynamics Inc.

AngioDynamics Inc. operates as a medical device company developing and manufacturing innovative devices for minimally invasive procedures in oncology, vascular access, and peripheral vascular disease applications. The company's specialized medical focus makes ANGO stock price sensitive to healthcare spending trends, regulatory approvals, and medical device market dynamics.

The company's product portfolio includes devices for cancer treatment, vascular access, and blood clot removal that enable physicians to perform less invasive procedures with improved patient outcomes. AngioDynamics' expertise in interventional medicine supports development of innovative treatment options for complex medical conditions.

ANGO stock price benefits from increasing adoption of minimally invasive medical procedures, growing cancer treatment demand, and technological advancement in interventional medicine. The company's devices often provide alternatives to more invasive surgical procedures while improving patient recovery times.

AngioDynamics' focus on innovation and clinical evidence development positions the company to expand its market presence in specialized medical device markets. The company's research and development investments and regulatory expertise support ANGO stock price growth potential as healthcare providers increasingly adopt minimally invasive treatment approaches across various medical specialties.

ANGO Stock 12 Month Chart


Latest News for ANGO

AngioDynamics (ANGO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...

The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business ...

AngioDynamics beat earnings this morning. The company did that not by earning more than expected, though, but by losing less than expected. Full-year earnings will still be negative. Heading into the ...